What is ribociclib?

Ribociclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used to treat certain types of breast cancer. It was developed by Novartis and marketed under the trade name Kisqali. Riboxiclib (Riboxiclib) blocks the progression of the G1 phase of the cell cycle by inhibiting the activities of CDK4 and CDK6, thereby preventing the proliferation of cancer cells.

Ribociclib is specifically indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer, often in combination with an aromatase inhibitor (such as letrozole) or other endocrine therapies (such as fulvestrant). Its mechanism of action is based on intervention in cell cycle regulation: CDK4/6 combines with cyclin D to promote cells from The span>G1 phase enters the S phase, thereby carrying out DNA replication. By inhibiting CDK4/6, ribociclib (ribociclib) causes cells to stay in the G1 phase and cannot undergo further cell division.

Clinical studies have shown that ribociclib (ribociclib) has a significant effect in prolonging progression-free survival (PFS). For example, the MONALEESA-2 trial showed that ribociclib combined with letrozole significantly prolonged PFS in patients with previously untreated advanced breast cancer. Such research results have promoted Ribociclib as a first-line drug for the treatment of HR+/HER2- breast cancer.

Common side effects of ribociclib include neutropenia, elevated liver enzymes, nausea, fatigue, and hair loss. Because it may cause cardiacQTinterval prolongation, the electrocardiogram needs to be monitored regularly during use. The patient is receivingRibociclib (Riboxiclib) During treatment, blood routine and liver function should also be monitored.

In short,riboxiclib (riboxiclib) as an innovativeCDK4/6 inhibitor, provides an important treatment option for HR+/HER2- advanced breast cancer patients by effectively preventing the proliferation of cancer cells. Its use in combination with endocrine therapy has become a key means to extend the progression-free survival of patients. However, patients need to be closely monitored for side effects during use to ensure the safety and effectiveness of the treatment.